Purpose Oxidized low-density lipoprotein (oxLDL) plays a key role in endothelial dysfunction, vascular inflammation, and atherogenesis. The aim of this study was to assess blood clearance and in vivo kinetics of radiolabeled oxLDL in mice. Methods We synthesized 123 I-oxLDL by the iodine monochloride method, and performed an uptake study in CHO cells transfected with lectin-like oxLDL receptor-1 (LOX-1). In addition, we evaluated the consistency between the 123
Introduction
Oxidized low-density lipoprotein (oxLDL) is involved in vascular endothelial dysfunction, injury, and inflammation, and plays an important role in atherogenesis [1, 2] . When deposited in the aortic subendothelial layer of atherosclerotic lesions, oxLDL is endocytosed by macrophages, which become foam cells, leading to atherogenesis [3] . oxLDL is also closely associated with diabetes [4] , preeclampsia [5] , and osteoarthritis [6] . Epidemiological studies of oxLDL revealed that an elevated concentration of oxLDL in the blood is associated with an increased risk of cardiovascular diseases, including coronary disease [7] , ischemic stroke [8] , and metabolic syndrome [9] .
Once oxLDL enters the circulation, the liver is the major organ responsible for its removal from the blood. Specifically, Kupffer cells in the liver play an important role in removing oxLDL [10] , as demonstrated by studies using Kupffer cells isolated from human liver [11] and rabbit liver [12] . Therefore, the lifetime of oxLDL in the circulation is very short, and consequently, under normal physiological conditions, the oxLDL concentration in the blood is low. Clearance of oxLDL from the blood is also associated with protection against the pathological alterations caused by this protein [10] . The system that prevents oxLDL accumulation can deteriorate as a consequence of aging or disease, causing higher levels of oxLDL to remain in the blood [7] [8] [9] . Thus, the kinetics of oxLDL, including blood clearance and accumulation in various organs (not limited to the liver), might contribute to assessments of risk status for vascular diseases.
Several radiolabeled tracers have been applied to the in vivo kinetic studies of oxLDL. Ling et al. utilized iodine-125-labeled oxLDL ( 125 I-oxLDL) and demonstrated using extracted tissue samples that over 90% ID was cleared from the blood at 5 min post-injection in normal mice, and that 50% ID of 125 I-oxLDL accumulated in the liver [13] . Rapid clearance of 125 I-oxLDL from the blood and accumulation in the liver were also reported in rats [10] and in guinea pigs [14] . Sequential planar imaging in humans after i.v. injection of technetium-99 m-labeled oxLDL ( 99m Tc-oxLDL), followed by visual or qualitative observation, revealed that the labeled oxLDL mostly accumulated ine the liver. This observation suggested that high accumulation in the liver is the major cause of rapid clearance of oxLDL from the blood [15] . 125 I-oxLDL is not an ideal radio-ligand for in vivo imaging, due to the low energy of the gamma rays (30.5-35.3 keV) emitted from the 125 I isotope; this is particularly true in larger objects, which exhibit greater attenuation. Iodine-123 ( 123 I), which emits higher-energy gamma rays (159 keV), has been extensively utilized for clinical scans. With this isotope, application of suitable reconstruction procedures, including appropriate corrections for attenuation and scatter, enables quantitative imaging [16, 17] .
In this study, we developed a technique for synthesizing 
Materials and Methods

Subjects
Human LOX-1-transfected Chinese hamster ovary (hLOX-1-CHO) cells were used to evaluate the affinity of synthesized 1 2 3 I -o x L D L a n d 1 , 1 ′ -d i o c t a d e c y l -3 , 3 , 3 ′ , 3 ′ -tetramethylindocarbocyanine perchlorate-labeled oxLDL (DiIoxLDL). Detailed techniques for the preparation of the cells were described in a previous report [18] . Twenty seven C57BL/6 mice (CLEA Japan Inc., Tokyo, Japan), 10 weeks old at the time of the experiment, were used for in vivo imaging and ex vivo assessments. All mice were male, and average body weight was 22.7 ± 1.4 g. The mice were habituated for 2 weeks before the experiment in a controlled facility at 26°C and 40% humidity, and then provided with water and chow ad libitum.
Preparation of Labeled oxLDL
OxLDL was prepared as described previously [19] . In brief, native albumin-free low-density lipoprotein (LDL) was isolated by sequential ultracentrifugation from plasma obtained from healthy human male volunteers. The LDL was oxidized by exposure to 7.5 μM CuSO 4 for 16 h at 37°C at a protein concentration of 3 mg/ml in phosphate-buffered saline (PBS). The protein content of oxLDL was measured using a BCA protein assay kit (PIERCE, Rockford, IL, USA).
The oxLDL was labeled with 123 I as described previously [20] with some modifications. Iodine monochloride (ICl) (6.5 μl; 2600 nmol; Wako Pure Chemical Industries, Osaka, Japan) was added to a mixture of oxLDL (12.5 μl, 7 mg/ml; 0.05 nmol), to which was added [
123 I]NaI (111 MBq, 0.01 nmol in 0.04 M NaOH) from Fujifilm RI Pharma (Tokyo, Japan) in 1 M glycine/NaOH buffer (pH 10, 25 μl). The reaction proceeded for 10 min at 4°C, and then the mixture was separated by high-performance liquid chromatography (HPLC) (L-2130; Hitachi, Tokyo, Japan) on a sizeexclusion column (YMC-Pack Diol-200 (20 × 300 mm); YMC, Kyoto, Japan) eluted with buffer containing 150 mM NaCl and 0.24 mM EDTA at pH 7.4 (LDL buffer) at room temperature. At a flow rate of 1.0 ml/min, the retention time of 123 I-oxLDL was 7.5 min. The eluate containing 123 I-oxLDL (3 ml) was collected and concentrated to a volume of~60 μl by centrifugation in an Amicon Ultra-4® (50 kDa cutoff; Millipore, Billerica, MA, USA). The number of oxLDL molecules and radiochemical purity of 123 I-oxLDL were determined by size-exclusion HPLC, as described above (flow rate:
1.0 ml/min). The degree of oxidation, as indicated by relative electrophoretic mobility (REM) and thiobarbituric acidreactive substances (TBARS assay kits; ZeptoMetrix Corp, Buffalo, NY), were compared between before and after labeling with the 123 I using the ICl method. REM was calculated as the electrophoretic mobility to native-LDL ratio on agarose gels (Titan Gel Lipoprotein Kit 3045; Helena Laboratories, Beaumont, TX).
OxLDL was also labeled with DiI (Invitrogen, Carlsbad, CA, USA) as described previously [19] . Briefly, lipoprotein-deficient serum (LPDS; Sigma-Aldrich, St Louis, MO, USA) was added to yield a 1:5 ratio of oxLDL protein to LPDS protein. A stock solution of the fluorescent probe DiI was prepared by dissolving 30 mg DiI in 1 ml of dimethyl sulfoxide (DMSO; Wako Pure Chemical Industries). The stock DiI was added to the oxLDL-LPDS mixture to give a final concentration of 300 μg DiI/mg oxLDL. A fluorescent dye DiI (Ex: 549 nm, Em: 565 nm), which has lipophilic long-chain dialkylcarbocyanines in its structure, was used to stain the lipid protein components in oxLDL [21] . After this mixture was incubated for 18 h at 37°C, the labeled oxLDL was isolated by ultracentrifugation, dialyzed against LDL buffer, and filter sterilized.
Cellular Studies
Uptake of labeled oxLDL to hLOX-1-CHO cell was evaluated for both 123 I-oxLDL and DiI-oxLDL. Cells were washed twice with Ham's F-12/10 mM HEPES, and were subsequently incubated for 2 h at 37°C with 300 μl of Ham's F-12/ 10 mM HEPES containing various concentrations of oxLDL (0.03, 0.1, 0.3, 1.0, 3.0, and 10 μg of protein/ml), prepared by successive dilution of 123 I-oxLDL or DiI-oxLDL. Incubation was terminated by aspiration of the buffer and washing of the cell layers with PBS (500 μl × 2). The cells containing 123 IoxLDL were lysed with 0.2 M NaOH, and the radioactivity of the samples was measured using an automatic gamma counter (1480 WIZARD; PerkinElmer-Wallac, MA, USA). Protein concentrations of the sample cells were determined using the BCA protein assay kit. The cellular uptake of 123 I-oxLDL was calculated as counts per minute (cpm) divided by the amount of total cellular protein. Cells incubated with DiIoxLDL were fixed, counterstained with 4′,6-diamidino-2-phenylindole (DAPI; D9542, Sigma-Aldrich), and analyzed on an IN Cell Analyzer 1000 system (GE Healthcare, Waukesha, WI, USA). The total number of cell nuclei was counted in DAPI images. The cellular uptake of DiI-oxLDL was calculated as mean fluorescence intensity (MFI) divided by cell number.
Animal Studies
Twenty seven mice were studied by dividing into four groups as follows: (a) consistency of I-oxLDL from the blood, and (d) assessment of stability of 123 I-oxLDL in the serum. All mice were fasted for 12 h before the experiments began.
Experiment (a) Four mice were assigned to compare uptake of 123 I-oxLDL and DiI-oxLDL in the spleen and liver. In this study, conscious mice were injected via the tail vein with a mixture of DiI-oxLDL (1.10 ± 0.05 MBq, 15 μg protein/ 50 μl) and 123 I-oxLDL (15 μg protein/50 μl), so that the total amount of oxLDL was 30 μg/body (approximately 1.5 mg protein/kg). Animals were sacrificed by intraperitoneal administration of an overdose of pentobarbital (50 mg/ml, 150 μl) 10 min after injection. Animals were perfused with saline and perfusion-fixed with 4% paraformaldehyde phosphate buffer solution (PFA) (Wako Pure Chemical). Spleen and liver were excised and immersed in 4% PFA at 4°C overnight. Two consecutive slices (100 μm thickness) were obtained from each organ using a microslicer (DTK-Zero 1; DSK, Kyoto, Japan). Nuclei in sliced organ samples were counterstained with DAPI. The bright-field and fluorescence images of sliced organs were acquired with a fluorescence microscope (AZ100; Nikon, Tokyo, Japan) affixed to a CCD camera (DS-Fi1-U2; Nikon). The slices were then placed in contact with an imaging plate (BAS IP MS-2025, Fujifilm, Tokyo, Japan) for 24 h, and autoradiograms were acquired using an image plate reader (BAS 5000, Fujifilm).
Experiment (b)
Sixteen mice were used to investigate the whole-body organ distribution of radioactivity after i.v. injection of 123 I-oxLDL. Six mice among 16 were assigned to in vivo imaging prior to the ex vivo biodistribution study. Anesthesia was induced with 2% isoflurane, and subsequently maintained by intramuscular injection of ketamine (100 mg/ kg)-xylazine (10 mg/kg) cocktail. Animals were then placed on a custom-designed holder in the supine position, in whicih equally spaced marker holes of 8 μl volume at 25 mm separation may be filled with 0.1 MBq [ 123 I]NaI or gadoliniumdiethylenetriaminepentaacetic acid (Gd-DTPA) solution, and were referred to register the planar 123 I-oxLDL images to the MR images.
MR images were first obtained using a clinical 3 Tesla MRI scanner (Signa HD 3.0 T; GE Healthcare) fitted with an inhouse eight-channel receive-only RF coil (diameter, 50 mm) to assess the whole-body T1-weighted images [22] . After moving the animals to a clinical SPECT system (GCA-7200A; TOSHIBA, Tokyo, Japan) fitted with a low-energy high-resolution (LEHR) parallel-beam collimator, an 123 IoxLDL sample of 32.5 ± 12.6 MBq with 30 ± 2.5 μg protein/60 μl was injected into the tail vein by bolus (<1.0 s) via a 26-gauge cannula (Safelet-Cath; Nipro, Osaka, Japan). Images were corrected for inhomogeneous detector sensitivity, and also for spatial distortion. Planar images of radioactivity distribution in those animals were initiated 6 s before 123 I-oxLDL injection. The sequential planar imaging scan consisted of 246 frames of 1 s and 10 frames of 36 s, ending 600 s after 123 I-oxLDL administration. Those six animals were sacrificed immediately after the end of the planer imaging, and the entire liver, spleen, heart, lung, kidney, bladder, stomach, gut, and thyroid were excised. The whole tail was also taken, and the rest of the body was also excised as Bcarcass^. Total radioactivity and weights were assessed for each tissue sample and also for the blood. Weights were measured using an electronic balance (GR-60; A&D, Tokyo, Japan), and the radioactivity was measured using an automatic gamma counter.
The ex vivo biodistribution study was also carried out for another ten animals, in which animals were sacrificed at 2 min (n = 5) and at 5 min (n = 5) post i.v.
123
I-oxLDL, and tissue and blood samples were taken according to the same procedures as described for animals sacrificed at 10 min post injection of 123 I-oxLDL. Radioactivity and weights were measured according to the sample for animals sacrificed at 10 min post injection of 123 I-oxLDL.
Experiment (c)
In four mice, HPLC analysis was carried out on both 123 I-oxLDL and serum samples. 123 I-oxLDL (4.0 ± 1.2 MBq; 30 μg protein/60 μl) was injected into conscious mice, and a blood sample of approximately 800 μl was collected from the right ventricle 10 min post-injection. The blood sample was transferred to a serum separator tube (CAPIJECT CJ-AS; Terumo, Tokyo, Japan), and the tube was centrifuged for 15 min at 4°C (1500 × g). The supernatant was collected as serum. Approximately 400 μl of serum was diluted with LDL buffer and applied to the size-exclusion HPLC mentioned above (flow rate: 1.0 ml/min). Areas under the curves (AUCs) were assessed for the two peaks corresponding to I-oxLDL (1.0 MBq) was added to the serum (400 μl). After incubation for 2 h at 37°C, aliquots of the samples were drawn and the radioactivity was analyzed using size-exclusion HPLC at a flow rate of 1.0 ml/min.
Data Analysis
Cellular uptake of The 123 I-oxLDL autoradiograms images were coregistered to the DiI-oxLDL fluorescent images for both liver and spleen slices. The hepatic lobes were classified into two structures: around the central vein, and near the interlobular areas. The spleens were divided into three structures: white pulp, red pulp, and marginal zone. Three regions of interest (ROIs) (φ125 μm) were manually placed on each of these structures in two sections. Intensity values for each ROI were normalized against the average intensity at each section, and intensity values in ARG were compared with those of the fluorescence images. This image analysis was carried out using Fiji [23] .
In the in vivo dynamic imaging study, ROIs were carefully placed on MR coronal images co-registered to sequential planar images of 123 I-oxLDL to generate TACs for liver, heart, lungs, kidney, head, and abdomen. During ROI selection, care was taken to avoid the vena cava or the vasculature and bladder. TACs were calculated from sequential planar images using the AMIDE software [24] , and temporally smoothed at later stages to reduce the statistical noise. Average TACs from six mice were plotted based on the moving average. Significant differences were detected at each time point using the LabVIEW 8.6 software (National Instruments, TX USA).
In the ex vivo biodistribution study, percent injected dose (%ID) was calculated as the fractional uptake of radioactivity in each organ divided by the total injected radioactivity, and the dose uptake ratio (DUR) was calculated as radioactivity per unit mass of each organ divided by the injected dose over whole body weight, yielding a dimensionless index. These parameters were calculated for all nine organs from all six mice, as well as from carcass, blood, and tail samples. Assuming the total blood volume of 72 ml per body weight of kg [25] , the %ID and DUR were estimated from the measured radioactivity concentration of the sampled blood.
Fractions and calibrated radioactivity were assessed for the two peaks corresponding to Summarized data are presented as means ± standard deviation. Statistical analysis was performed by Mann-Whitney U test, or ANOVA followed by Bonferroni correction, with significance accepted at P < 0.05. Statistical analyses were performed in R [26] with the EZR graphical interface [27] .
Results
The radiochemical yield and purity of 123 I-oxLDL were 30.0 ± 12.8% and 90.3 ± 2.5%, respectively. The REM of oxLDL and 123 I-oxLDL were 2.11 ± 0.28 and 2.14 ± 0.22, respectively. The TBARS of oxLDL and 123 I-oxLDL were 23.9 ± 3.0 nmol/mg and 23.8 ± 3.9 nmol/mg, respectively. The amount of radioactivity administered to mice in the dynamic planar studies was 32.5 ± 12.6 MBq, and the dose of oxLDL was 30 ± 2.5 μg of protein. The specific radioactivity of Figure 1 shows the cellular uptake of oxLDL, measured using 123 I-oxLDL and DiI-oxLDL as tracers, in hLOX-1-CHO and control CHO cells. Note that the plotted values were normalized against the peak values for each of the ligands. Both 123 I-oxLDL and DiI-oxLDL exhibited significantly higher uptake in hLOX-1-CHO cells than in control CHO cells. In the hLOX-1-CHO cells, a dose-dependent increase was seen in both 123 I-oxLDL and DiI-oxLDL. We observed no difference between 123 I-oxLDL and DiI-oxLDL at any oxLDL concentrations. Fig. 2b) sections. The oxLDL uptake in the interlobular area was higher than that of the central vein area for both 123 I-oxLDL and DiI-oxLDL. In the spleen, the highest and lowest accumulation was observed in the marginal zone and white pulp, respectively. Quantitative analysis confirmed that the intensity values differed significantly among the three ROIs for DiI-oxLDL and 123 I-oxLDL (Table 1) . Dynamic planar images acquired following i.v. injection of 123 I-oxLDL are shown in Fig. 3 . These images show that the injected radioactivity moved from the right ventricle (at 2 s) to the left ventricle (at 3 s), and then to the lungs (2-4 s). Recirculated radioactivity arriving at the heart could also be seen around 7-8 s. Radioactivity then gradually accumulated in the liver~100 s post-injection. Ultimately, the radioactivity accumulated gradually throughout the body, which could not be seen in early phase images. Figure 4 shows TACs averaged over six mice for each of the six ROIs. The heart region exhibited an initial peak at 2 s and a second at 7 s post-injection; radioactivity in the heart region subsequently decreased to a plateau after 200 s. TAC for the lung was similar to that of the heart. The kidney region exhibited an initial peak at 4 s post-injection, and then the radioactivity decreased to a constant level after approximately 30 s. In the liver, TAC increased and reached a plateau at 200 s post-injection. Marked accumulation of radioactivity was not observed in the head or abdomen regions. Figure 5 shows %ID and DUR of mice at 2, 5, and 10 min after injection of 123 I-oxLDL. The DUR of 123 I-oxLDL in the liver, spleen, heart, and lungs were higher than that in the blood (Fig. 5a ). The summed %ID over these organs was 50.0 ± 2.3%, and the remaining half of the radioactivity was mainly in the carcass. Accumulation of radioactivity in the entire carcass was 39.4 ± 2.7% ID, almost equal to that of the liver 40.8 ± 2.4% ID (Fig. 5b) . DUR and %ID in the kidney, bladder, and thyroid were low: 0.94 ± 0.13, 0.93 ± 0.07, and 0.89 ± 0.18 for DUR, and 1.71 ± 0.22, 0.41 ± 0.04, and 0.69 ± 0.18 for %ID, respectively. None of samples showed significant changes among different time points for both %ID and DUR. Figure 6 shows the results of size-exclusion radiochromatographic analysis of (Fig. 6a) . Most of the 123 I-oxLDL fraction had disappeared from the serum by 10 min post-injection (Fig. 6b) . A considerable reduction of I-oxLDL in murine serum as evaluated in vitro using size-exclusion HPLC analysis was 94.5 ± 2.3% (n = 3) in the beginning, and was 88.8 ± 3.5% at 2 h after the incubation. The degradation was approximately 94% even after 2 h of incubation at 37°C, which is greater than a typical value of 90% considered as a stability reference. (Fig. 2a) and spleen (Fig. 2b) . Bright field (1), DiI fluorescence (2), and ARG (3) images are shown. Enlarged fluorescence images merged with nuclei image of hepatic lobule and spleen slices are also shown (4). In the liver slice, a star represents the central vein, and triangles the interlobular area, including the interlobular artery and vein of the hepatic lobule. In the spleen slice, circles represent red pulp, rectangles the white pulp, and diamonds the marginal zone. Circular regions of interest (ROIs) of 125 μm diameter were placed on each of those regions I efficiently by the direct method [20] , with a radiochemical yield of 30% and purity of 90%. The degree of oxidation, as indicated by REM and TBARS, did differ before and after labeling of oxLDL by 123 I using the ICl method. Notably, the specific radioactivity of 2700 GBq/ μmol was considerably higher than that of previously reported oxLDLs labeled with other radioisotopes, such as 125 I-oxLDL (6-7 GBq/μmol) [10, 13, 14] , 99m Tc-labeled oxLDL (300-900 GBq/μmol) [15] , and fluorine-18-labeled oxLDL (200- I-oxLDL. Accumulation of radioactivity in the heart, followed by the liver, is apparent. A small but significant distribution of radioactivity can also be seen in the whole body, particularly at later stages Oxidizing agents are not used during the labeling process of DiI-oxLDL, which is widely used in cellular and in vivo studies [19, 30, 31] . Uptake of 123 I-oxLDL by hLOX-1-CHO cells increased in a dose-dependent manner, and was approximately 15 times higher than that in control CHO cells. Notably, the uptake of 123 I-oxLDL was very similar to that of DiI-oxLDL, as demonstrated in Fig. 1 . This suggested that the binding properties of 123 I-oxLDL are comparable to those of DiI-oxLDL, suggesting that the oxidation procedures used during the synthesis of 123 I-oxLDL are unlikely to have altered the binding properties of oxLDL. In fact, the slice comparison shown in Fig. 2 and Table 1 indicated that distributions were consistent between 123 I-oxLDL ARG and DiIoxLDL fluorescence images of the liver and spleen.
123 IoxLDL uptake in the liver was higher in the interlobular area, which includes the interlobular artery and vein, but lower in the vicinity of the central vein. In the interlobular area, uptake is mediated by scavenger receptors on Kupffer cells. Evidence for selective expression of a receptor for oxLDL has been obtained in liver Kupffer cells isolated from rat [10] , human [11] , and rabbit [12] . The highest uptake of oxLDL in the spleen were observed at the marginal zone, followed by red pulp, for both types of labeled oxLDL. The marginal zone is an important transition area, and the most distinctive cell type in this region is the marginal-zone macrophage, which expresses the type I scavenger receptor MRCO [32] . The reduced contrast among regions in the 123 I-oxLDL autoradiogram in comparison with the DiI-oxLDL fluorescence images shown in Table 1 On the basis of previous ex vivo biodistribution studies [10, 13, 14] and human dynamic planar scintigraphy [15] , oxLDL is thought to be rapidly cleared from blood due to high liver uptake. Our whole-body dynamic planar imaging in mice also clearly visualized the decrease in radioactivity in the heart, concomitant with accumulation of radioactivity in the liver, under anesthetized conditions (Fig. 3) . The liver contained the highest level of radioactivity, which reached a plateau after 200 s (Fig. 4) . The TAC of the heart exhibited an initial peak at 2 s and a second at 7 s post-injection; the interval between these peaks was 5 s, corresponding to the whole-body recirculation time in mice [33] . In the biodistribution study, we found that %ID was approximately 40% in the liver, and 20% in other specifically excised organs (Fig. 5b) at 10 min post injection of 123 I-oxLDL. In addition, radioactivity equal to that in the liver was distributed in the rest of the body (carcass). This distribution was almost completed in 2 min after i.v. injection of 123 I-oxLDL, which is compatible with the results of the in vivo imaging study (Figs. 3 and 4) . Radioactivity of collected blood was 2.91 ± 0.76% ID, indicating that total %ID of blood was~9.2% ID, calculated based on the assumption that the total blood volume of mice is 72 ml/kg [25] . Therefore, the total radioactivity of residual blood in the mouse body, including organs, was calculated to be approximately 6.3% ID; thus, 123 I-oxLDL was incorporated and retained in particular organs or tissues within 10 min. The carcass includes brain, skeletal muscle, fat, genitalium, vasculature, and skin. The planar image and TAC revealed no specific accumulation of radioactivity in the brain or bone (Figs. 3 and 4) . Thus, the radioactivity of the carcass was very low, but widely distributed throughout the whole body. Therefore, we predict that vessels or muscle fiber in skeletal muscle and/or fat might contribute to oxLDL kinetics. Further studies should seek to identify the accumulation sites and mechanism that regulate the 
